Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial
Filip Jansåker, Sara Thønnings, Frederik Boëtius Hertz, Thomas Kallemose, Jan Værnet, Lars Bjerrum, Thomas Benfield, Niels Frimodt-Møller, Jenny Dahl Knudsen
Dive into the research topics of 'Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial'. Together they form a unique fingerprint.